OptimizeRx (NASDAQ:OPRX) Given New $5.00 Price Target at Barclays

by · The Cerbat Gem

OptimizeRx (NASDAQ:OPRX – Free Report) had its target price trimmed by Barclays from $11.00 to $5.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

A number of other research firms also recently issued reports on OPRX. JMP Securities decreased their price target on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research note on Thursday. B. Riley began coverage on shares of OptimizeRx in a research note on Thursday, July 25th. They issued a “buy” rating and a $18.50 price target for the company. Finally, Royal Bank of Canada decreased their price target on shares of OptimizeRx from $17.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, August 16th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.42.

View Our Latest Research Report on OptimizeRx

OptimizeRx Trading Down 5.9 %

Shares of NASDAQ:OPRX traded down $0.24 during midday trading on Thursday, hitting $3.82. 534,590 shares of the stock traded hands, compared to its average volume of 142,274. The business’s 50 day moving average is $6.67 and its two-hundred day moving average is $9.03. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.07 and a current ratio of 3.07. OptimizeRx has a one year low of $3.78 and a one year high of $16.65.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. First Light Asset Management LLC grew its holdings in shares of OptimizeRx by 5.1% during the second quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock valued at $18,270,000 after buying an additional 89,377 shares during the last quarter. Vanguard Group Inc. raised its position in OptimizeRx by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock worth $12,482,000 after acquiring an additional 6,291 shares during the period. AWM Investment Company Inc. raised its position in OptimizeRx by 4.0% in the first quarter. AWM Investment Company Inc. now owns 853,042 shares of the company’s stock worth $10,364,000 after acquiring an additional 33,000 shares during the period. Blair William & Co. IL raised its position in OptimizeRx by 5.6% in the first quarter. Blair William & Co. IL now owns 782,573 shares of the company’s stock worth $9,508,000 after acquiring an additional 41,469 shares during the period. Finally, Rice Hall James & Associates LLC raised its position in OptimizeRx by 24.0% in the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock worth $4,751,000 after acquiring an additional 119,306 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

(Get Free Report)

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

See Also